PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16268477-0 2005 Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor. Prasugrel Hydrochloride 95-101 purinergic receptor P2Y12 Homo sapiens 133-138 18278193-0 2008 The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Prasugrel Hydrochloride 133-142 purinergic receptor P2Y12 Homo sapiens 25-30 17598013-9 2007 In conclusion, R-138727, the active metabolite of prasugrel, results in rapid, potent, consistent, and selective inhibition of P2Y(12)-mediated up-regulation of thrombo-inflammatory markers of platelet activation. Prasugrel Hydrochloride 50-59 purinergic receptor P2Y12 Homo sapiens 127-134 16769598-0 2006 Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans. Prasugrel Hydrochloride 53-62 purinergic receptor P2Y12 Homo sapiens 95-100 16769598-0 2006 Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans. Prasugrel Hydrochloride 64-70 purinergic receptor P2Y12 Homo sapiens 95-100 16769599-0 2006 Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans. Prasugrel Hydrochloride 53-62 purinergic receptor P2Y12 Homo sapiens 95-100 16769599-0 2006 Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans. Prasugrel Hydrochloride 64-70 purinergic receptor P2Y12 Homo sapiens 95-100 18174449-3 2008 Novel P2Y12 antagonists, including prasugrel, AZD6140, and cangrelor, have a faster onset of action, as well as more potent, and less variable, inhibition of platelet function ex vivo. Prasugrel Hydrochloride 35-44 purinergic receptor P2Y12 Homo sapiens 6-11 16268477-0 2005 Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor. Prasugrel Hydrochloride 114-122 purinergic receptor P2Y12 Homo sapiens 133-138 32795098-1 2020 BACKGROUND: Standard administration of newer oral P2Y12 inhibitors, including prasugrel or ticagrelor, provides suboptimal early inhibition of platelet aggregation (IPA) in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Prasugrel Hydrochloride 78-87 purinergic receptor P2Y12 Homo sapiens 50-55 15967851-0 2005 Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Prasugrel Hydrochloride 25-34 purinergic receptor P2Y12 Homo sapiens 78-83 34106029-3 2021 The indication for one of the P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) is dependent on the treatment strategy; whether the patients undergo coronary angiography or are treated medically only. Prasugrel Hydrochloride 61-70 purinergic receptor P2Y12 Homo sapiens 30-35 34242414-6 2021 Alternative P2Y12 inhibitors (prasugrel or ticagrelor) were used less often in the older group than the younger group in patients with a CYP2C19 no function allele (55% vs. 67%; p=0.02) and in patients without a no function allele (10% vs. 35%, p<0.001). Prasugrel Hydrochloride 30-39 purinergic receptor P2Y12 Homo sapiens 12-17 34664214-13 2021 Ranking by p-score suggests prasugrel as the best P2Y12 inhibitor to reduce the risk of MACE while clopidogrel is a better alternative than ticagrelor in older patients with acute coronary syndrome to decrease the risk of major bleeding. Prasugrel Hydrochloride 28-37 purinergic receptor P2Y12 Homo sapiens 50-55 34815751-3 2021 Previous guidance has been provided regarding the classification of high-risk CCS and the use of newer-generation P2Y12 inhibitors (i.e. ticagrelor and prasugrel) after acute coronary syndromes (ACS) in Asia. Prasugrel Hydrochloride 152-161 purinergic receptor P2Y12 Homo sapiens 114-119 34755215-7 2021 Prasugrel is the P2Y12 inhibitor of choice in ST-segment elevation myocardial infarction (STEMI), but despite the impact of the ISAR-REACT 5 trial on selection of antiplatelet therapy, ticagrelor is still favored over prasugrel in NSTE-ACS. Prasugrel Hydrochloride 0-9 purinergic receptor P2Y12 Homo sapiens 17-22 34275780-8 2021 Median VASP index was significantly lower with the newer P2Y12 inhibitors (14% under ticagrelor, 14% under prasugrel) than with clopidogrel (42%). Prasugrel Hydrochloride 107-116 purinergic receptor P2Y12 Homo sapiens 57-62 34651261-7 2022 RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE: The current guidelines recommend potent P2Y12 prasugrel or ticagrelor for 12 months despite their association with a high risk of bleeding. Prasugrel Hydrochloride 95-104 purinergic receptor P2Y12 Homo sapiens 89-94 34137238-1 2021 BACKGROUND: The use of potent P2Y12 inhibitors (ticagrelor & prasugrel) in acute coronary syndrome (ACS) patients undergoing percutaneous coronary interventions (PCI) is a class I recommendation. Prasugrel Hydrochloride 61-70 purinergic receptor P2Y12 Homo sapiens 30-35 34319489-2 2021 Since purine receptor P2Y12 plays a crucial role in platelet activation, P2Y12 antagonists such as clopidogrel, prasugrel, and ticagrelor have been widely used in cardiovascular diseases worldwide in recent decades due to their potent antiplatelet and antithrombotic effects. Prasugrel Hydrochloride 112-121 purinergic receptor P2Y12 Homo sapiens 22-27 34319489-2 2021 Since purine receptor P2Y12 plays a crucial role in platelet activation, P2Y12 antagonists such as clopidogrel, prasugrel, and ticagrelor have been widely used in cardiovascular diseases worldwide in recent decades due to their potent antiplatelet and antithrombotic effects. Prasugrel Hydrochloride 112-121 purinergic receptor P2Y12 Homo sapiens 73-78 34234079-8 2021 Although the number of CYP2C19 loss-of-function alleles was clearly associated with a likelihood of HPR with clopidogrel, P2Y12 reactivity units with prasugrel treatment were also significantly and progressively higher in patients with more CYP2C19 loss-of-function alleles. Prasugrel Hydrochloride 150-159 purinergic receptor P2Y12 Homo sapiens 122-127 34377702-9 2021 He responded well to prasugrel (another P2Y12 inhibitor) in combination with aspirin. Prasugrel Hydrochloride 21-30 purinergic receptor P2Y12 Homo sapiens 40-45 34234079-9 2021 CONCLUSIONS: Clinical and genetic factors had a differential effect on a P2Y12 inhibitor reactivity with clopidogrel and prasugrel in patients with coronary artery disease. Prasugrel Hydrochloride 121-130 purinergic receptor P2Y12 Homo sapiens 73-78 34167672-1 2021 OBJECTIVES: This study sought to compare the pharmacodynamic effects of pre-hospitally administered P2Y12 inhibitor prasugrel in crushed versus integral tablet formulation in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI). Prasugrel Hydrochloride 116-125 purinergic receptor P2Y12 Homo sapiens 100-105 34169260-3 2021 Methods: Five members of the Canadian Cardiovascular Society antiplatelet therapy 2018 guidelines committee undertook an independent, evidence-based review to outline patients for whom prasugrel should be the optimal P2Y12 agent and discuss alternative strategies to consider without prasugrel. Prasugrel Hydrochloride 185-194 purinergic receptor P2Y12 Homo sapiens 217-222 34207339-1 2021 East Asians treated with potent P2Y12 inhibitors (prasugrel or ticagrelor) generally experience more intense platelet inhibitory responses resulting in an increased risk of major bleeding. Prasugrel Hydrochloride 50-59 purinergic receptor P2Y12 Homo sapiens 32-37 35566604-1 2022 BACKGROUND: East Asian patients receiving treatment with the potent P2Y12 inhibitors prasugrel or ticagrelor experience more potent platelet inhibition than with clopidogrel. Prasugrel Hydrochloride 85-94 purinergic receptor P2Y12 Homo sapiens 68-73 35001413-4 2022 In patients with acute cerebrovascular disease, aspirin combined with clopidogrel reduces subsequent risk, while in acute coronary syndrome, dual antiplatelet therapy comprising aspirin and a P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) confers greater protection than aspirin monotherapy, with prasugrel and ticagrelor offering greater antiplatelet efficacy with faster onset of action than clopidogrel. Prasugrel Hydrochloride 222-231 purinergic receptor P2Y12 Homo sapiens 192-197 35621210-10 2022 Many patients (16.4%) had a >1-hour gap between cangrelor cessation and oral P2Y12 inhibitor initiation; this was highest among those transitioned to clopidogrel (56.6% versus 34.5% prasugrel versus 10.8% ticagrelor; P<0.001). Prasugrel Hydrochloride 182-191 purinergic receptor P2Y12 Homo sapiens 77-82 35514270-12 2022 CONCLUSION: Prasugrel and ticagrelor inhibit P2Y12 - and PAR-mediated platelet aggregation in individuals with diabetes to a similar extent, irrespective of HbA1c levels and BMI. Prasugrel Hydrochloride 12-21 purinergic receptor P2Y12 Homo sapiens 45-50 35090983-1 2022 BACKGROUND: The safety and efficacy of potent P2Y12 inhibitors (Ticagrelor and Prasugrel) in dual antiplatelet therapy (DAPT) with aspirin in elderly acute coronary syndrome (ACS) patients remains unclear. Prasugrel Hydrochloride 79-88 purinergic receptor P2Y12 Homo sapiens 46-51 33582955-1 2021 Prasugrel and ticagrelor are potent oral platelet P2Y12 inhibitors and are recommended over clopidogrel in patients with acute coronary syndrome (ACS). Prasugrel Hydrochloride 0-9 purinergic receptor P2Y12 Homo sapiens 50-55 35407624-2 2022 In Japan, clopidogrel was the major P2Y12 inhibitor used for a decade until the new P2Y12 inhibitor, prasugrel, was introduced. Prasugrel Hydrochloride 101-110 purinergic receptor P2Y12 Homo sapiens 36-41 35407624-2 2022 In Japan, clopidogrel was the major P2Y12 inhibitor used for a decade until the new P2Y12 inhibitor, prasugrel, was introduced. Prasugrel Hydrochloride 101-110 purinergic receptor P2Y12 Homo sapiens 84-89 33993817-2 2021 The potent P2Y12 inhibitors, prasugrel and ticagrelor, can overcome this limitation but at the expense of an increased risk of bleeding. Prasugrel Hydrochloride 29-38 purinergic receptor P2Y12 Homo sapiens 11-16 33955698-4 2021 Long-term benefit is provided by oral P2Y12 receptor antagonists such as clopidogrel, prasugrel, and ticagrelor. Prasugrel Hydrochloride 86-95 purinergic receptor P2Y12 Homo sapiens 38-43 33113567-1 2021 Compared to clopidogrel, prasugrel has a lower incidence of ischemic events following percutaneous coronary intervention (PCI) because of an early reduction during the acute phase in P2Y12 reaction units (PRU). Prasugrel Hydrochloride 25-34 purinergic receptor P2Y12 Homo sapiens 183-188 35428703-1 2022 BACKGROUND: Currently, potent P2Y12 inhibition with the use of prasugrel or ticagrelor is the mainstay of treatment after an acute coronary syndrome (ACS). Prasugrel Hydrochloride 63-72 purinergic receptor P2Y12 Homo sapiens 30-35 35294730-4 2022 The benefit of more potent P2Y12 inhibitors such as ticagrelor or prasugrel in stable patients is unproven, but their use might be reasonable in those with high clinical or angiographic features of increased ischemic risk without increased risk of bleeding. Prasugrel Hydrochloride 66-75 purinergic receptor P2Y12 Homo sapiens 27-32 35115197-5 2022 After switching to prasugrel, mean P2Y12 reaction units (PRU) values were significantly reduced in both EM and RM populations, while the proportion of high on-treatment platelet reactivity (HPR) patients significantly declined in RM patients. Prasugrel Hydrochloride 19-28 purinergic receptor P2Y12 Homo sapiens 35-40 33309519-6 2021 The antagonism of platelet P2Y12 receptors by cangrelor, ticagrelor or active metabolites of the thienopyridine compounds ticlopidine, clopidogrel and prasugrel reduces the ADP-induced platelet aggregation in patients with thrombotic complications of vascular diseases. Prasugrel Hydrochloride 151-160 purinergic receptor P2Y12 Homo sapiens 27-32 33877270-2 2021 Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) reduces cardiovascular event rates after ACS. Prasugrel Hydrochloride 107-116 purinergic receptor P2Y12 Homo sapiens 62-67 33877270-10 2021 The newest P2Y12 inhibitors, prasugrel and ticagrelor, are more potent, with high on-treatment residual platelet reactivity of about 3% vs 30% to 40% with clopidogrel and act within 30 minutes compared with 2 hours for clopidogrel. Prasugrel Hydrochloride 29-38 purinergic receptor P2Y12 Homo sapiens 11-16 33758122-6 2021 Another recently published VORA-PRATIC (Vorapaxar in Patients with Prior Myocardial Infarction Treated with prasugrel and ticagrelor) study showed that among post-MI patients treated with potent P2Y12 inhibitors (prasugrel or ticagrelor), vorapaxar reduced platelet-driven global thrombogenicity, an effect that persisted, albeit attenuated, in the absence of aspirin. Prasugrel Hydrochloride 108-117 purinergic receptor P2Y12 Homo sapiens 195-200 33758122-6 2021 Another recently published VORA-PRATIC (Vorapaxar in Patients with Prior Myocardial Infarction Treated with prasugrel and ticagrelor) study showed that among post-MI patients treated with potent P2Y12 inhibitors (prasugrel or ticagrelor), vorapaxar reduced platelet-driven global thrombogenicity, an effect that persisted, albeit attenuated, in the absence of aspirin. Prasugrel Hydrochloride 213-222 purinergic receptor P2Y12 Homo sapiens 195-200 33693287-0 2020 Effects of Vonoprazan on the Antiplatelet Function of Prasugrel Assessed by the VerifyNow P2Y12 Assay in Patients With Coronary Artery Disease. Prasugrel Hydrochloride 54-63 purinergic receptor P2Y12 Homo sapiens 90-95 33674980-0 2021 NSTE-ACS ESC Guidelines Recommend Prasugrel as the Preferred P2Y12 Inhibitor: A Contrarian View. Prasugrel Hydrochloride 34-43 purinergic receptor P2Y12 Homo sapiens 61-66 33708263-2 2021 Newer generation P2Y12 inhibitors (i.e. ticagrelor and prasugrel) have demonstrated improved clinical outcomes compared with clopidogrel. Prasugrel Hydrochloride 55-64 purinergic receptor P2Y12 Homo sapiens 17-22 33412611-0 2021 Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor. Prasugrel Hydrochloride 120-129 purinergic receptor P2Y12 Homo sapiens 76-81 32152791-3 2020 Prasugrel and ticagrelor are more potent P2Y12 inhibitors than clopidogrel and commonly substituted for clopidogrel when HPR is documented, however benefit of VN guided intensified antiplatelet therapy is uncertain. Prasugrel Hydrochloride 0-9 purinergic receptor P2Y12 Homo sapiens 41-46 32513604-2 2020 Prasugrel and ticagrelor are commonly used P2Y12 inhibitors, and a few head-to-head randomized control trials (RCTs) have been performed. Prasugrel Hydrochloride 0-9 purinergic receptor P2Y12 Homo sapiens 43-48 32390477-3 2020 The newer P2Y12 inhibitors (prasugrel and ticagrelor) have better efficacy than clopidogrel. Prasugrel Hydrochloride 28-37 purinergic receptor P2Y12 Homo sapiens 10-15 33654473-2 2020 In the last decade, the arrival of prasugrel and ticagrelor, faster and more powerful oral platelet receptor P2Y12 inhibitors compared to clopidogrel, significantly improved platelet inhibition in patients with ACS. Prasugrel Hydrochloride 35-44 purinergic receptor P2Y12 Homo sapiens 109-114 32974447-6 2020 P2Y12 reaction units (PRU) measured using VerifyNow assay was 282, suggesting high platelet reactivity on prasugrel. Prasugrel Hydrochloride 106-115 purinergic receptor P2Y12 Homo sapiens 0-5 31165176-9 2020 CONCLUSION: Half-dose (30 mg) prasugrel loading results in effective platelet P2Y12 receptor inhibition in more than 98% of patients. Prasugrel Hydrochloride 30-39 purinergic receptor P2Y12 Homo sapiens 78-83 31542850-1 2020 INTRODUCTION: Despite the use of the new generation P2Y12 inhibitors (Ticagrelor and Prasugrel) with aspirin is the recommended therapy in acute NSTE-ACS patients, their current use in clinical practice remains quite low and might be related, among several variables, with increased comorbidity burden. Prasugrel Hydrochloride 85-94 purinergic receptor P2Y12 Homo sapiens 52-57 32821149-2 2020 Current clinical practice guidelines now recommend more potent P2Y12 inhibitors (prasugrel or ticagrelor) over clopidogrel in acute coronary syndrome (ACS). Prasugrel Hydrochloride 81-90 purinergic receptor P2Y12 Homo sapiens 63-68 32629976-1 2020 In recent years, much progress has been made in the field of antithrombotic drugs in acute coronary syndrome (ACS) treatment, as reflected by the introduction of the more potent P2Y12-inhibitors prasugrel and ticagrelor, and novel forms of concomitant anticoagulation, such as fondaparinux and bivalirudin. Prasugrel Hydrochloride 195-204 purinergic receptor P2Y12 Homo sapiens 178-183 32585929-2 2020 Current clinical guidelines recommend novel P2Y12 inhibitors (e.g., prasugrel or ticagrelor) in addition to aspirin based on the results of representative randomized controlled trials conducted predominantly in Western countries. Prasugrel Hydrochloride 68-77 purinergic receptor P2Y12 Homo sapiens 44-49 32074647-2 2020 The past 30 years has seen the progress from early trials of clopidogrel and glycoprotein IIb/IIIa inhibitors to the application of more potent P2Y12 inhibitors prasugrel and ticagrelor. Prasugrel Hydrochloride 161-170 purinergic receptor P2Y12 Homo sapiens 144-149 32272255-3 2020 Evidence suggests that administration of crushed tablets of the P2Y12 inhibitor prasugrel improves drug absorption and achieves earlier antiplatelet effects in STEMI patients undergoing primary percutaneous coronary intervention (PCI). Prasugrel Hydrochloride 80-89 purinergic receptor P2Y12 Homo sapiens 64-69 32081368-0 2020 Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor. Prasugrel Hydrochloride 92-101 purinergic receptor P2Y12 Homo sapiens 75-80 32305225-15 2020 In conclusion, in this network meta-analysis, prasugrel showed the highest efficacy in reducing adverse outcomes in ACS patients and had the highest probability of being the best P2Y12 inhibitor to reduce hard adverse events both at 30-day and 1-year follow-up. Prasugrel Hydrochloride 46-55 purinergic receptor P2Y12 Homo sapiens 179-184 31675507-4 2019 This study aimed to evaluate the in vitro effects of different contrast agents on the antiaggregant activity of P2Y12 inhibitors (clopidogrel, ticagrelor and prasugrel). Prasugrel Hydrochloride 158-167 purinergic receptor P2Y12 Homo sapiens 112-117 30983087-6 2020 RESULTS: Antiplatelet reactivity in the prasugrel treatment group reached optimal levels (P2Y12 reaction units [PRU] less than 262) immediately after the administration and was maintained even at 8 months, independently of the CYP2C19 genotype. Prasugrel Hydrochloride 40-49 purinergic receptor P2Y12 Homo sapiens 90-95 30922852-5 2019 The nucleoside analogue ticagrelor and active metabolites of the thienopyridine compounds ticlopidine, clopidogrel and prasugrel inhibit platelet P2Y12 receptors and reduce thereby platelet aggregation. Prasugrel Hydrochloride 119-128 purinergic receptor P2Y12 Homo sapiens 146-151 31242837-1 2019 BACKGROUND: Dual antiplatelet therapy (DAPT) with aspirin and one of inhibitors of P2Y12 receptors (clopidogrel, ticagrelor, prasugrel) is an international standard of receptors (clopidogrel, ticagrelor, prasugrel) is an international standard of is an international standard of treatment strategy in patients with acute coronary syndrome (ACS). Prasugrel Hydrochloride 125-134 purinergic receptor P2Y12 Homo sapiens 83-88 31242837-1 2019 BACKGROUND: Dual antiplatelet therapy (DAPT) with aspirin and one of inhibitors of P2Y12 receptors (clopidogrel, ticagrelor, prasugrel) is an international standard of receptors (clopidogrel, ticagrelor, prasugrel) is an international standard of is an international standard of treatment strategy in patients with acute coronary syndrome (ACS). Prasugrel Hydrochloride 204-213 purinergic receptor P2Y12 Homo sapiens 83-88 31197411-1 2019 PURPOSE: The POPular Risk Score was developed for the selective intensification of P2Y12 inhibitor treatment with prasugrel instead of clopidogrel in patients undergoing non-urgent percutaneous coronary intervention (PCI) with stent implantation. Prasugrel Hydrochloride 114-123 purinergic receptor P2Y12 Homo sapiens 83-88 31202949-2 2019 The availability of different P2Y12 receptor inhibitors (clopidogrel, prasugrel, ticagrelor) with varying levels of potency has enabled physicians to contemplate individualized treatment regimens, which may include escalation or de-escalation of P2Y12-inhibiting therapy. Prasugrel Hydrochloride 70-79 purinergic receptor P2Y12 Homo sapiens 30-35 31198410-3 2019 The most used P2Y12-antagonists are clopidogrel, prasugrel and ticagrelor. Prasugrel Hydrochloride 49-58 purinergic receptor P2Y12 Homo sapiens 14-19 31294325-9 2019 Conclusion: Normal platelet aggregation via PAR-1 and PAR-4 is preserved in many patients with adequate P2Y12 inhibition by prasugrel and ticagrelor. Prasugrel Hydrochloride 124-133 purinergic receptor P2Y12 Homo sapiens 104-109 31294325-7 2019 Among the 112 prasugrel-treated patients with adequate P2Y12 inhibition, 50 patients (45%) still had a normal response to SFLLRN, and 70 patients (63%) still had a normal response to AYPGKF. Prasugrel Hydrochloride 14-23 purinergic receptor P2Y12 Homo sapiens 55-60 31070112-5 2019 Higher potency P2Y12 inhibitors (prasugrel or ticagrelor) were prescribed at discharge in 39%, 35%, 23%, and 15% ( P<0.01) of patients with stages 1, 2, 3, and >=4, respectively. Prasugrel Hydrochloride 33-42 purinergic receptor P2Y12 Homo sapiens 15-20 30876967-1 2019 The pharmacological and clinical differences of the three recommended oral P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) enable physicians to switch from one agent to another that it is considered more appropriate in the specific clinical setting. Prasugrel Hydrochloride 106-115 purinergic receptor P2Y12 Homo sapiens 75-80 30760018-1 2019 Current guidelines recommend dual antiplatelet therapy-a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and aspirin-for patients undergoing percutaneous coronary intervention. Prasugrel Hydrochloride 87-96 purinergic receptor P2Y12 Homo sapiens 57-62 30882670-1 2019 Although the new oral P2Y12 inhibitors, prasugrel/ticagrelor have shown greater efficacy than clopidogrel in patients with the acute coronary syndrome, but they have not shown better efficacy in Korean patients. Prasugrel Hydrochloride 40-49 purinergic receptor P2Y12 Homo sapiens 22-27 30685502-3 2019 The availability of different oral P2Y12 antagonists (clopidogrel, prasugrel, ticagrelor) along with the introduction of the first intravenous P2Y12 antagonist cangrelor offer an opportunity to individualize antiplatelet therapy according to the changing clinical setting. Prasugrel Hydrochloride 67-76 purinergic receptor P2Y12 Homo sapiens 35-40 30723937-5 2019 Recently, more data have emerged using alternative P2Y12 inhibitors such as prasugrel and ticagrelor. Prasugrel Hydrochloride 76-85 purinergic receptor P2Y12 Homo sapiens 51-56 30456635-2 2019 New generation P2Y12 inhibitors (ticagrelor and prasugrel) might potentially replace clopidogrel for the treatment of post-interventional acute coronary syndrome (ACS). Prasugrel Hydrochloride 48-57 purinergic receptor P2Y12 Homo sapiens 15-20 30641247-1 2019 BACKGROUND: Prasugrel as a second generation P2Y12 adenosine diphosphate receptor antagonist which in the cerebral aneurysms with Endovascular treatment have become more emphasized. Prasugrel Hydrochloride 12-21 purinergic receptor P2Y12 Homo sapiens 45-50 30614864-2 2019 In current clinical situation, availability of different oral P2Y12 inhibitors (clopidogrel, prasugrel, and ticagrelor) has enabled physicians to switch among therapies owing to specific clinical scenarios. Prasugrel Hydrochloride 93-102 purinergic receptor P2Y12 Homo sapiens 62-67 30689068-2 2019 Treating ACS patients with dual antiplatelet therapy (DAPT) for a year by combining aspirin and a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) has resulted in better outcomes and is currently the standard of therapy. Prasugrel Hydrochloride 143-152 purinergic receptor P2Y12 Homo sapiens 98-103 29412111-2 2019 Of them, adenosine diphosphate receptor P2Y12 inhibitors clopidogrel, prasugrel and ticagrelor are currently used for post-ACS long-term treatment. Prasugrel Hydrochloride 70-79 purinergic receptor P2Y12 Homo sapiens 40-45 29890239-3 2019 OBJECTIVE: We sought to determine whether treatment with prasugrel, which inhibits platelet activation by blocking the type 12 purinergic (P2Y12) receptor, would attenuate the severity of sinonasal and respiratory symptoms induced during aspirin challenge in patients with AERD. Prasugrel Hydrochloride 57-66 purinergic receptor P2Y12 Homo sapiens 139-144 29890239-12 2019 In a small subset of patients with AERD who had greater baseline platelet activation and milder upper respiratory symptoms during aspirin-induced reactions, P2Y12 receptor antagonism with prasugrel completely inhibited all aspirin-induced reaction symptoms, suggesting a contribution from P2Y12 receptor signaling in this subset. Prasugrel Hydrochloride 188-197 purinergic receptor P2Y12 Homo sapiens 157-162 29890239-12 2019 In a small subset of patients with AERD who had greater baseline platelet activation and milder upper respiratory symptoms during aspirin-induced reactions, P2Y12 receptor antagonism with prasugrel completely inhibited all aspirin-induced reaction symptoms, suggesting a contribution from P2Y12 receptor signaling in this subset. Prasugrel Hydrochloride 188-197 purinergic receptor P2Y12 Homo sapiens 289-294 30734681-4 2019 P2Y12 inhibitors, i.e. clopidogrel, prasugrel, ticagrelor, and cangrelor, are already used clinically to reduce coronary artery thrombosis risk and prevent acute coronary syndromes. Prasugrel Hydrochloride 36-45 purinergic receptor P2Y12 Homo sapiens 0-5 30103241-1 2018 BACKGROUND: Phenotype-guided de-escalation (PGDE) of P2Y12-inhibitor treatment with an early switch from prasugrel to clopidogrel was identified as an effective alternative treatment strategy in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). Prasugrel Hydrochloride 106-115 purinergic receptor P2Y12 Homo sapiens 54-59 30648108-9 2018 Conclusions: This meta-analysis of RCTs shows that, compared with clopidogrel, novel oral P2Y12 inhibitors, especially prasugrel, might have better effect on improving ventricular rhythm and cardiac function. Prasugrel Hydrochloride 119-128 purinergic receptor P2Y12 Homo sapiens 90-95 30196683-3 2018 We investigated changes in the value of P2Y12 resistance unit (PRU) when prasugrel was administered to patients with clopidogrel resistance. Prasugrel Hydrochloride 73-82 purinergic receptor P2Y12 Homo sapiens 40-45 30478067-1 2018 OBJECTIVE: After finding that the thienopyridines clopidogrel and prasugrel reduced migraine headache (MHA) symptoms in some patients with patent foramen ovale (PFO), this small pilot study was undertaken to determine whether ticagrelor, a nonthienopyridine P2Y12 inhibitor, would have similar MHA effects and might be better suited for a future randomized trial. Prasugrel Hydrochloride 66-75 purinergic receptor P2Y12 Homo sapiens 258-263 30238704-5 2018 Our review focusses on P2Y12 receptor therapy de-escalation defined as a switch from a potent antiplatelet agent (ticagrelor or prasugrel) to clopidogrel. Prasugrel Hydrochloride 128-137 purinergic receptor P2Y12 Homo sapiens 23-28 29568240-5 2018 Results: Prasugrel consistently inhibited adenosine diphosphate receptor P2Y12 signalling to abolish amplification of platelet aggregation. Prasugrel Hydrochloride 9-18 purinergic receptor P2Y12 Homo sapiens 73-78 29150850-3 2018 Ticagrelor and prasugrel are two latest generation P2Y12 inhibitors with advantageous platelet inhibitory profiles. Prasugrel Hydrochloride 15-24 purinergic receptor P2Y12 Homo sapiens 51-56 29336311-4 2018 During the early stages of the trial, the P2Y12 inhibitor of choice was prasugrel with some use of clopidogrel. Prasugrel Hydrochloride 72-81 purinergic receptor P2Y12 Homo sapiens 42-47 29799992-12 2018 Conclusions and Relevance: Between 2008 and 2016, increased use of prasugrel and ticagrelor was accompanied by increased nonfilling of prescriptions for P2Y12 inhibitors within 30 days of discharge. Prasugrel Hydrochloride 67-76 purinergic receptor P2Y12 Homo sapiens 153-158 29146484-1 2018 INTRODUCTION AND OBJECTIVES: Acute coronary syndrome (ACS) guidelines recommend the use of newer P2Y12 inhibitors (prasugrel and ticagrelor) over clopidogrel in patients with moderate-to-high ischemic risk, unless they have an increased bleeding risk. Prasugrel Hydrochloride 115-124 purinergic receptor P2Y12 Homo sapiens 97-102 28982722-1 2018 OBJECTIVE: To estimate the absolute treatment effects of newer P2Y12 inhibitors (ticagrelor and prasugrel) compared with clopidogrel in men and women with acute coronary syndrome (ACS). Prasugrel Hydrochloride 96-105 purinergic receptor P2Y12 Homo sapiens 63-68 29338536-4 2018 Therefore, we summarize data from relevant preclinical and clinical trials of currently approved P2Y12 receptor inhibitors (clopidogrel, prasugrel, ticagrelor, cangrelor) and provide strategies of drug switching and management of bleeding events. Prasugrel Hydrochloride 137-146 purinergic receptor P2Y12 Homo sapiens 97-102 29215418-1 2018 Ticagrelor and prasugrel are newer antiplatelet drugs which, like clopidogrel, block the P2Y12 platelet receptor to inhibit platelet aggregation. Prasugrel Hydrochloride 15-24 purinergic receptor P2Y12 Homo sapiens 89-94 29215418-3 2018 Therefore, some institutions and providers switch patients from ticagrelor or prasugrel to clopidogrel in an effort to lower bleeding risk, stem costs, or otherwise ensure that patients can safely adhere to long-term P2Y12 inhibitor therapy. Prasugrel Hydrochloride 78-87 purinergic receptor P2Y12 Homo sapiens 217-222 29043405-4 2017 In patients with ACS the question arises when treatment with one of the more potent P2Y12 inhibitors, such as prasugrel and ticagrelor should be used instead of clopidogrel. Prasugrel Hydrochloride 110-119 purinergic receptor P2Y12 Homo sapiens 84-89 29782272-2 2018 In this article we present data of major randomized trials of clopidogrel and novel P2Y12 inhibitors - prasugrel, ticagrelor, cangrelor - assessing strategy of administration of antiaggregants in patients with ACS before coronary angiography / percutaneous coronary intervention. Prasugrel Hydrochloride 103-112 purinergic receptor P2Y12 Homo sapiens 84-89 29534250-1 2018 Third-generation P2Y12 inhibitors (prasugrel, ticagrelor) are recommended in acute myocardial infarction (AMI). Prasugrel Hydrochloride 35-44 purinergic receptor P2Y12 Homo sapiens 17-22 29456511-8 2018 Thus, P2Y12R antagonists, including clopidogrel, ticagrelor, and prasugrel, might represent potential anti-cancer agents, in addition to their role as effective antithrombotic drugs. Prasugrel Hydrochloride 65-74 purinergic receptor P2Y12 Homo sapiens 6-12 28403576-2 2018 Prasugrel is a platelet inhibitor that acts as a P2Y12 receptor antagonist through an active metabolite, R-138727. Prasugrel Hydrochloride 0-9 purinergic receptor P2Y12 Homo sapiens 49-54 29224649-1 2018 BACKGROUND: The use of the potent oral P2Y12 inhibitors prasugrel and ticagrelor in patients with acute coronary syndromes (ACS) has a favorable net clinical effect compared with clopidogrel and is recommended as first-line therapy. Prasugrel Hydrochloride 56-65 purinergic receptor P2Y12 Homo sapiens 39-44 29300792-9 2017 Newer oral P2Y12 inhibitors such as ticagrelor and prasugrel have demonstrated greater efficacy than clopidogrel in improving the cardiovascular outcomes of patients with ACS and diabetes. Prasugrel Hydrochloride 51-60 purinergic receptor P2Y12 Homo sapiens 11-16 28267384-1 2017 Three oral platelet P2Y12 inhibitors, clopidogrel, prasugrel, and ticagrelor, are available for reducing the risk of cardiovascular death and stent thrombosis in patients with acute coronary syndromes (ACS). Prasugrel Hydrochloride 51-60 purinergic receptor P2Y12 Homo sapiens 20-25 29084738-2 2017 The availability of different oral P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) has enabled physicians to contemplate switching among therapies because of specific clinical scenarios. Prasugrel Hydrochloride 66-75 purinergic receptor P2Y12 Homo sapiens 35-40 29225903-7 2017 Results: Prasugrel or ticagrelor was given as the loading P2Y12 inhibitor in 49% of 2198 patients and as a maintenance therapy in 59%. Prasugrel Hydrochloride 9-18 purinergic receptor P2Y12 Homo sapiens 58-63 28618904-4 2017 The aim of this article is to provide an overview of the evidence from randomized clinical trials with a focus on the best association between aspirin and a P2Y12 inhibitor such as clopidogrel, prasugrel or ticagrelor, on the selection of the appropriate agent based on the revascularization strategy and on the optimal duration of such an intensive treatment. Prasugrel Hydrochloride 194-203 purinergic receptor P2Y12 Homo sapiens 157-162 26752652-4 2017 The most recent thienopyridine, prasugrel, allows an irreversible inhibition of the P2Y12 platelet receptor associated to a faster and more consistent onset of action rather the previous antiplatelet agents of the same class. Prasugrel Hydrochloride 32-41 purinergic receptor P2Y12 Homo sapiens 84-89 27488859-0 2017 Changes in P2Y12 reaction units after switching treatments from prasugrel to clopidogrel in Japanese patients with acute coronary syndrome followed by elective coronary stenting. Prasugrel Hydrochloride 64-73 purinergic receptor P2Y12 Homo sapiens 11-16 28776172-3 2017 As compared with clopidogrel, these newer P2Y12 agents-such as prasugrel and ticagrelor-allow for further reductions in ischemic end points, without the robust increases in bleeding seen in previous studies of antithrombotic therapies. Prasugrel Hydrochloride 63-72 purinergic receptor P2Y12 Homo sapiens 42-47 28653184-0 2017 Reversal of the platelet inhibitory effect of the P2Y12 inhibitors clopidogrel, prasugrel, and ticagrelor in vitro: a new approach to an old issue. Prasugrel Hydrochloride 80-89 purinergic receptor P2Y12 Homo sapiens 50-55 28204303-5 2017 Insufficient P2Y12-inhibition or high on-treatment platelet reactivity to adenosine diphosphate has stimulated the increased use of more potent P2Y12 inhibitors: prasugrel (a third generation thienopyridine) and ticagrelor (a cyclopentyl-triazolo-pyrimidine). Prasugrel Hydrochloride 162-171 purinergic receptor P2Y12 Homo sapiens 144-149 28833345-1 2017 STUDY OBJECTIVE: To describe contemporary trends of P2Y12 inhibitor use in patients with acute coronary syndrome (ACS) and comorbid diabetes mellitus (DM) and/or chronic kidney disease (CKD) who have a higher risk of recurring ACS and may benefit from treatment with higher efficacy third-generation agents (prasugrel and ticagrelor). Prasugrel Hydrochloride 308-317 purinergic receptor P2Y12 Homo sapiens 52-57 28463894-7 2017 Pharmacokinetic/pharmacodynamic studies confirmed a more prompt and potent platelet inhibition after loading with the new P2Y12 inhibitors versus clopidogrel, and suggested the safety of switching from prasugrel to ticagrelor. Prasugrel Hydrochloride 202-211 purinergic receptor P2Y12 Homo sapiens 122-127 28562105-3 2017 Areas covered: The oral thienopyridine, prasugrel hydrochloride, irreversibly inhibits the P2Y12 receptors, inhibiting ADP-dependent platelet activation. Prasugrel Hydrochloride 40-63 purinergic receptor P2Y12 Homo sapiens 91-96 28520385-2 2012 Prasugrel, along with other antiplatelet agents such as clopidogrel and ticagrelor, inhibits platelet activation by irreversibly binding to the platelet receptor, P2RY12. Prasugrel Hydrochloride 0-9 purinergic receptor P2Y12 Homo sapiens 163-169 28045759-1 2017 The efficacy and safety of novel oral P2Y12 receptor inhibitors (prasugrel and ticagrelor) are subjects of contention in patients with ST-segment elevation myocardial infarction (STEMI) undergoing PCI, and the optimal duration of therapy remains uncertain. Prasugrel Hydrochloride 65-74 purinergic receptor P2Y12 Homo sapiens 38-43 28089137-11 2017 CONCLUSION: Despite rapid platelet inhibition provided by cangrelor, newer oral P2Y12 inhibitors such as ticagrelor and prasugrel have comparable clinical outcomes. Prasugrel Hydrochloride 120-129 purinergic receptor P2Y12 Homo sapiens 80-85 26124456-8 2017 The powerful oral P2Y12 inhibitors, prasugrel and ticagrelor, have been clearly shown to prevent stent thrombosis and recurrent ischaemic events after emergency percutaneous coronary intervention in STEMI patients. Prasugrel Hydrochloride 36-45 purinergic receptor P2Y12 Homo sapiens 18-23 27922911-4 2017 The newer P2Y12 inhibitors include cangrelor, prasugrel, and ticagrelor. Prasugrel Hydrochloride 46-55 purinergic receptor P2Y12 Homo sapiens 10-15 28062136-0 2017 P2Y12 receptor inhibition with prasugrel and ticagrelor in STEMI patients after fibrinolytic therapy: Analysis from the SAMPA randomized trial. Prasugrel Hydrochloride 31-40 purinergic receptor P2Y12 Homo sapiens 0-5 28062136-10 2017 Ticagrelor and prasugrel demonstrated a similar extent of P2Y12 receptor inhibition within 24h, although maximal platelet inhibition after these potent agents was not achieved for 6h. Prasugrel Hydrochloride 15-24 purinergic receptor P2Y12 Homo sapiens 58-63 27628008-7 2017 The antiplatelet effect of the new P2Y12 receptor antagonists, ticagrelor and prasugrel, seems less influenced by PPI co-treatment.Given the large number of patients treated with antithrombotic drugs and PPIs, even a minor reduction of platelet inhibition potentially carries considerable clinical impact. Prasugrel Hydrochloride 78-87 purinergic receptor P2Y12 Homo sapiens 35-40 27617370-3 2017 The new P2Y12 inhibitors, ticagrelor and prasugrel, have been shown to be superior to clopidogrel in STEMI patients undergoing primary percutaneous coronary intervention. Prasugrel Hydrochloride 41-50 purinergic receptor P2Y12 Homo sapiens 8-13 28184261-1 2017 Dual antiplatelet therapy (DAPT) consisting of aspirin plus a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) is imperative for the treatment of acute coronary syndrome, particularly during the re-endothelialization period after percutaneous coronary intervention (PCI). Prasugrel Hydrochloride 92-101 purinergic receptor P2Y12 Homo sapiens 62-67 28184261-5 2017 After this period, it is generally recommended that the P2Y12 inhibitor be stopped for the amount of time necessary for platelet function recovery (clopidogrel 5-7 days, prasugrel 7-10 days, ticagrelor 3-5 days), and that aspirin be continued during the perioperative period. Prasugrel Hydrochloride 170-179 purinergic receptor P2Y12 Homo sapiens 56-61 27734075-9 2017 In conclusion, in contrast to previous reports describing a significant delay in onset of prasugrel-mediated P2Y12 inhibition in acute STEMI, we observed a rapid onset with low HTPR rates comparable to those observed in stable non-STEMI patients. Prasugrel Hydrochloride 90-99 purinergic receptor P2Y12 Homo sapiens 109-114 27734075-10 2017 Prasugrel administered directly after primary PCI might therefore be a useful therapeutic strategy in patients with STEMI to provide strong and effective P2Y12 inhibition. Prasugrel Hydrochloride 0-9 purinergic receptor P2Y12 Homo sapiens 154-159 28058211-5 2016 Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor such as clopidogrel, prasugrel and ticagrelor is instated post stenting to decrease the incident of ST. Cangrelor has recently been approved by Food and Drug Administration and can be used as a bridging antiplatelet drug. Prasugrel Hydrochloride 89-98 purinergic receptor P2Y12 Homo sapiens 52-57 28810251-1 2017 BACKGROUND: The optimal dosing of novel oral P2Y12 receptor platelet inhibitors such as prasugrel or ticagrelor is unclear and especially challenging in East Asians. Prasugrel Hydrochloride 88-97 purinergic receptor P2Y12 Homo sapiens 45-50 24942006-1 2016 Dual antiplatelet therapy comprising aspirin and a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) is essential to prevent thrombotic complications after percutaneous coronary intervention (PCI). Prasugrel Hydrochloride 81-90 purinergic receptor P2Y12 Homo sapiens 51-56 26690314-8 2016 CONCLUSIONS: This IABP-SHOCK II trial subgroup analysis shows that the use of potent P2Y12 receptor inhibitors like prasugrel or ticagrelor is feasible and might not be harmful in selected patients with cardiogenic shock complicating acute myocardial infarction. Prasugrel Hydrochloride 116-125 purinergic receptor P2Y12 Homo sapiens 85-90 27318323-1 2016 Previously, we showed preventive effects of prasugrel, a P2Y12 antagonist, in a non-human primate model of thrombotic middle cerebral artery occlusion (MCAO); however, it remains unclear if P2Y12 inhibition after MCAO reduces cerebral injury and dysfunction. Prasugrel Hydrochloride 44-53 purinergic receptor P2Y12 Homo sapiens 57-62 26802900-4 2016 Existing oral P2Y12 receptors inhibitors (clopidogrel, prasugrel, or ticagrelor) have several limitations such as delayed onset and offset of action, interindividual variation, and only oral availability. Prasugrel Hydrochloride 55-64 purinergic receptor P2Y12 Homo sapiens 14-19 27309035-2 2016 Currently, three P2Y12 receptor inhibitors are approved for clinical use, including clopidogrel, prasugrel, and ticagrelor, with the latter two being preferred in patients presenting with an acute coronary syndrome. Prasugrel Hydrochloride 97-106 purinergic receptor P2Y12 Homo sapiens 17-22 26953527-1 2016 Pretreatment with oral P2Y12 inhibitors occurs each time clopidogrel, prasugrel, ticagrelor are given to patients with suspected coronary artery disease before definition of the coronary anatomy. Prasugrel Hydrochloride 70-79 purinergic receptor P2Y12 Homo sapiens 23-28 27264219-2 2016 At the present time, 3 different oral P2Y12 receptor inhibitors are available on the market; 2 have obtained the indication for ACS (clopidogrel and ticagrelor) and 1 for ACS with planned PCI (prasugrel). Prasugrel Hydrochloride 193-202 purinergic receptor P2Y12 Homo sapiens 38-43 26556524-1 2016 To evaluate the pharmacodynamic efficacy of de-escalating P2Y12 inhibition from prasugrel to clopidogrel based on cytochrome P450 (CYP) 2C19 genotyping, we genotyped 50 Korean patients with AMI who underwent percutaneous coronary intervention (PCI) for CYP2C19 *2,*3, or *17 using real-time PCR. Prasugrel Hydrochloride 80-89 purinergic receptor P2Y12 Homo sapiens 58-63 27012781-8 2016 RESULTS: Compared with whole tablets, crushed prasugrel led to reduced P2Y12 reaction units by 30 min post-LD, which persisted at 1, 2 (164 vs. 95; least square mean difference = 68; 95% confidence interval: 10 to 126; primary endpoint), and 4 h post-LD. Prasugrel Hydrochloride 46-55 purinergic receptor P2Y12 Homo sapiens 71-76 26340851-0 2016 Antiplatelet efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) in patients treated with mild therapeutic hypothermia after cardiac arrest due to acute myocardial infarction. Prasugrel Hydrochloride 43-52 purinergic receptor P2Y12 Homo sapiens 25-30 26712838-4 2016 Although the rationale for pre-treatment is obvious, large-scale randomized trials supporting a pre-treatment strategy with clopidogrel or with the newer P2Y12inhibitors prasugrel and ticagrelor did not exist. Prasugrel Hydrochloride 170-179 purinergic receptor P2Y12 Homo sapiens 154-159 26554025-11 2016 Potent irreversible P2Y12 inhibition by prasugrel does not affect LPS-induced coagulation activation. Prasugrel Hydrochloride 40-49 purinergic receptor P2Y12 Homo sapiens 20-25 27385702-8 2016 Hypersensitivity manifesting as a rash has been previously reported in patients receiving prasugrel, a thienopyridine P2Y12 inhibitor. Prasugrel Hydrochloride 90-99 purinergic receptor P2Y12 Homo sapiens 118-123 27464285-1 2016 For secondary prevention of acute coronary syndrome, guidelines recommend dual antiplatelet therapy with acetylsalicylic acid and a P2Y12 receptor antagonist such as clopidogrel, prasugrel or ticagrelor for a period of 12 months. Prasugrel Hydrochloride 179-188 purinergic receptor P2Y12 Homo sapiens 132-137 27533757-9 2016 Regarding individual P2Y12 inhibitors, patients on prasugrel, and, to a lesser degree, ticagrelor, had fewer ischaemic and bleeding events at all time points than clopidogrel-treated patients. Prasugrel Hydrochloride 51-60 purinergic receptor P2Y12 Homo sapiens 21-26 27310147-2 2016 Administration of newer P2Y12 inhibitors (prasugrel and ticagrelor) combined with aspirin has been shown to reduce the incidence of sub-acute and late stent thrombosis, compared with clopidogrel. Prasugrel Hydrochloride 42-51 purinergic receptor P2Y12 Homo sapiens 24-29 26790884-10 2016 Despite a significant delay compared to stable AMI patients, sufficient platelet inhibition was reached in 83 % of patients within 24 h. Therefore, prasugrel administration via gastric tube might be a useful therapeutic strategy in these patients at high risk, providing potent and effective P2Y12 inhibition. Prasugrel Hydrochloride 148-157 purinergic receptor P2Y12 Homo sapiens 292-297 26554025-3 2016 Prasugrel, a potent irreversible inhibitor of P2Y12 receptor-induced platelet activation may reduce activation of coagulation in a human LPS (lipopolysaccharide) model. Prasugrel Hydrochloride 0-9 purinergic receptor P2Y12 Homo sapiens 46-51 26846581-3 2016 tested the hypothesis that platelet inhibition by prasugrel, a potent platelet P2Y12 ADP receptor antagonist, attenuates the effect of lipopolysaccharide (LPS) on the blood coagulation system in healthy human subjects. Prasugrel Hydrochloride 50-59 purinergic receptor P2Y12 Homo sapiens 79-84 25850030-6 2016 Treatment with prasugrel significantly reduced HPR compared with clopidogrel by P2Y12 reaction unit (PRU) thresholds of >234 (0 vs 24.1%, P=0.0046) and PRU>208 (3.3 vs 34.5%, P=0.0025). Prasugrel Hydrochloride 15-24 purinergic receptor P2Y12 Homo sapiens 80-85 27262327-4 2016 RESULTS: Added to aspirin, clopidogrel, prasugrel and ticagrelor represent viable options regarding oral P2Y12 inhibition, with prasugrel and ticagrelor being preferred over clopidogrel, according to results of large randomized clinical trials. Prasugrel Hydrochloride 40-49 purinergic receptor P2Y12 Homo sapiens 105-110 26444255-5 2016 Cangrelor blocks the binding to the platelet P2Y12 receptor of the active metabolite of the thienopyridines, clopidogrel and prasugrel. Prasugrel Hydrochloride 125-134 purinergic receptor P2Y12 Homo sapiens 45-50 26270719-0 2016 Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro. Prasugrel Hydrochloride 76-85 purinergic receptor P2Y12 Homo sapiens 89-94 26270719-8 2016 In conclusion, in vitro cangrelor strongly inhibits the binding of clopidogrel and prasugrel AMs to the P2Y12 receptor, consistent with the previous observation of a negative pharmacodynamic interaction. Prasugrel Hydrochloride 83-92 purinergic receptor P2Y12 Homo sapiens 104-109 27590033-1 2016 Dual antiplatelet therapy (DAPT) with acetylsalicylic acid and a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) reduces thrombotic events in patients with acute coronary syndrome (ACS), but it is also associated with an increased risk of bleeding complications. Prasugrel Hydrochloride 110-119 purinergic receptor P2Y12 Homo sapiens 65-70 26402735-1 2015 OBJECTIVE: New P2Y12 inhibitors, classified as oral (prasugrel and ticagrelor) and intravenous (cangrelor and elinogrel) drugs, have shown improved antithrombotic effects compared with clopidogrel in patients with acute coronary syndrome (ACS) or patients undergoing percutaneous coronary intervention (PCI) in landmark trials. Prasugrel Hydrochloride 53-62 purinergic receptor P2Y12 Homo sapiens 15-20 26717223-2 2015 We hypothesized that in diabetic patients undergoing percutaneous coronary intervention, who exhibit high-platelet-reactivity after standard treatment with clopidogrel, a 60-mg prasugrel loading dose is superior to standard treatment with clopidogrel for optimal P2Y12 inhibition within the first 24-36 h post-angioplasty. Prasugrel Hydrochloride 177-186 purinergic receptor P2Y12 Homo sapiens 263-268 26553698-3 2015 METHODS AND RESULTS: In the Antagonize P2Y12 Treatment Inhibitors by Transfusion of Platelets in an Urgent or Delayed Timing After Acute Coronary Syndrome or Percutaneous Coronary Intervention Presentation-Acute Coronary Syndrome (APTITUDE-ACS) study, patients presenting with acute coronary syndrome or for elective percutaneous coronary intervention, receiving loading doses of clopidogrel (600 mg, n=13 or 900 mg, n=12), prasugrel 60 mg (n=10), or ticagrelor 180 mg (n=10) were included. Prasugrel Hydrochloride 424-433 purinergic receptor P2Y12 Homo sapiens 39-44 26542508-1 2015 RATIONALE: Dual antiplatelet therapy with acetylsalicylic acid in combination with a more potent P2Y12- inhibitor (ticagrelor or prasugrel) is recommended in patients with acute coronary syndrome without ST-segment elevation (NSTE-ACS) to prevent atherothrombotic complications. Prasugrel Hydrochloride 129-138 purinergic receptor P2Y12 Homo sapiens 97-102 26553698-0 2015 Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study. Prasugrel Hydrochloride 116-125 purinergic receptor P2Y12 Homo sapiens 83-88 26063049-3 2015 The thienopyridine class of P2Y12 receptor antagonists, clopidogrel and prasugrel, have demonstrated efficacy. Prasugrel Hydrochloride 72-81 purinergic receptor P2Y12 Homo sapiens 28-33 26553698-5 2015 The percentage restoration of residual platelet aggregation achieved with 80% proportion PT (residual platelet aggregation 80% PT mix/residual platelet aggregation baselinex100) significantly decreased with increasing potency of P2Y12 RI (83.9+-11%, 73+-14%, 66.3+-15%, 40.9+-19% for clopidogrel 600 mg, clopidogrel 900 mg, prasugrel, and ticagrelor, respectively; P for trend <0.0001). Prasugrel Hydrochloride 324-333 purinergic receptor P2Y12 Homo sapiens 229-234 26113418-1 2015 In patients with acute coronary syndrome, dual antiplatelet therapy with aspirin and a P2Y12 inhibitor like prasugrel is prescribed for one year. Prasugrel Hydrochloride 108-117 purinergic receptor P2Y12 Homo sapiens 87-92 26119655-0 2015 Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome. Prasugrel Hydrochloride 64-73 purinergic receptor P2Y12 Homo sapiens 46-51 26119655-3 2015 A systemic search of MEDLINE and EMBASE databases was performed to identify randomized clinical trials comparing newer oral P2Y12 inhibitors (prasugrel or ticagrelor) to clopidogrel in patients with NSTE-ACS. Prasugrel Hydrochloride 142-151 purinergic receptor P2Y12 Homo sapiens 124-129 26374625-2 2015 Prasugrel, which is a new P2Y12 inhibitor, has been confirmed as efficacious in a large trial in Western countries, and a similar trial is also to be launched in Asian countries. Prasugrel Hydrochloride 0-9 purinergic receptor P2Y12 Homo sapiens 26-31 26354056-1 2015 BACKGROUND/AIMS: Newer P2Y12 inhibitors, such as prasugrel and ticagrelor, have greater antiplatelet efficacy but may increase the risk of bleeding. Prasugrel Hydrochloride 49-58 purinergic receptor P2Y12 Homo sapiens 23-28 26205445-2 2015 BACKGROUND: Prasugrel is one of the preferred P2Y12 platelet receptor antagonists for ST-segment elevation myocardial infarction patients. Prasugrel Hydrochloride 12-21 purinergic receptor P2Y12 Homo sapiens 46-51 25994355-1 2015 The newer oral P2Y12 inhibitors prasugrel and ticagrelor have been reported to be more potent and faster-acting antiplatelet agents than clopidogrel. Prasugrel Hydrochloride 32-41 purinergic receptor P2Y12 Homo sapiens 15-20 26049376-5 2015 In contrast to clopidogrel, combining the more potent P2Y12 inhibitors (prasugrel and ticagrelor) with OAC may only be considered in certain specific circumstances. Prasugrel Hydrochloride 72-81 purinergic receptor P2Y12 Homo sapiens 54-59 25904241-6 2015 Antiplatelet therapy including the COX inhibitor aspirin and/or ADP receptor P2Y12 inhibitors such as clopidogrel, prasugrel and ticagrelor are the therapy of choice for various cardiovascular complications. Prasugrel Hydrochloride 115-124 purinergic receptor P2Y12 Homo sapiens 77-82 26156883-7 2015 The more potent thienopyridine P2Y12 inhibitor, prasugrel, has been shown to decrease platelet P-selectin expression and platelet-leukocyte aggregate formation compared to clopidogrel. Prasugrel Hydrochloride 48-57 purinergic receptor P2Y12 Homo sapiens 31-36 26092274-2 2015 Newer P2Y12 inhibitors like prasugrel and ticagrelor, which provide faster and stronger platelet inhibition compared with clopidogrel, would enhance the benefits of pretreatment. Prasugrel Hydrochloride 28-37 purinergic receptor P2Y12 Homo sapiens 6-11 26149010-9 2015 New drugs, such as prasugrel and ticagrelor, which effectively inhibit P2Y12R in the vast majority of patients, have proved to be more efficacious than clopdidogrel in preventing major adverse cardiovascular events. Prasugrel Hydrochloride 19-28 purinergic receptor P2Y12 Homo sapiens 71-77 25895737-2 2015 More potent P2Y12 inhibitors such as ticagrelor and prasugrel are associated with better pharmacodynamic effect and improved clinical outcomes but are associated with an increased risk of bleeding compared to clopidogrel. Prasugrel Hydrochloride 52-61 purinergic receptor P2Y12 Homo sapiens 12-17 25728969-3 2015 The latest guidelines include updated recommendations for the use of the oral antiplatelet agents (P2Y12 inhibitors) prasugrel and ticagrelor as part of dual-antiplatelet therapy-the cornerstone of treatment for these patients. Prasugrel Hydrochloride 117-126 purinergic receptor P2Y12 Homo sapiens 99-104 25893318-0 2015 Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies. Prasugrel Hydrochloride 27-36 purinergic receptor P2Y12 Homo sapiens 11-16 25585230-5 2015 When combined with aspirin, the new P2Y12 receptor inhibitors prasugrel and ticagrelor provide superior efficacy for the diabetic patients with acute coronary syndromes. Prasugrel Hydrochloride 62-71 purinergic receptor P2Y12 Homo sapiens 36-41 25732742-3 2015 Consequently, novel anti-platelets agents including the P2Y12 receptor antagonists, such as prasugrel and ticagrelor, have emerged. Prasugrel Hydrochloride 92-101 purinergic receptor P2Y12 Homo sapiens 56-61 25976494-2 2015 Oral antiplatelet agents for secondary prevention include the cyclo-oxygenase-1 inhibitor aspirin, and the ADP dependent P2Y12 inhibitors clopidogrel, prasugrel and ticagrelor. Prasugrel Hydrochloride 151-160 purinergic receptor P2Y12 Homo sapiens 121-126 25728969-6 2015 For example, the AHA/ACC recommends the P2Y12 inhibitor ticagrelor over clopidogrel in all patients with NSTE-ACS and clopidogrel, prasugrel, or ticagrelor for patients in whom percutaneous coronary intervention is planned, whereas the ESC guidelines specifically recommend individual P2Y12 inhibitors for particular patient subgroups. Prasugrel Hydrochloride 131-140 purinergic receptor P2Y12 Homo sapiens 40-45 25697420-2 2015 Two novel antiplatelet agents, ticagrelor and prasugrel, have been shown to rapidly and more effectively inhibit the P2Y12 receptor compared with clopidogrel. Prasugrel Hydrochloride 46-55 purinergic receptor P2Y12 Homo sapiens 117-122 25440595-4 2015 Recently developed antiplatelet agents (prasugrel, ticagrelor, cangrelor and elinogrel) efficiently antagonize P2Y12 receptor, a key platelet activating signaling pathway, and thereby inhibit aggregation induced by mediators such as ADP, collagen, thrombin and TXA2. Prasugrel Hydrochloride 40-49 purinergic receptor P2Y12 Homo sapiens 111-116 25633751-2 2015 Prasugrel is a third-generation thienopyridine whose metabolites target the P2Y12 receptor. Prasugrel Hydrochloride 0-9 purinergic receptor P2Y12 Homo sapiens 76-81 25633751-3 2015 Compared with clopidogrel, prasugrel has a more potent, faster in onset, and more consistent P2Y12 receptor inhibition. Prasugrel Hydrochloride 27-36 purinergic receptor P2Y12 Homo sapiens 93-98 25633751-8 2015 Prasugrel is currently challenged by ticagrelor, a P2Y12 receptor antagonist with different pharmacokinetic/pharmacodynamic properties. Prasugrel Hydrochloride 0-9 purinergic receptor P2Y12 Homo sapiens 51-56 25592204-3 2015 Dual antiplatelet therapy comprising aspirin plus a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) is recommended for patients with NSTE-ACS, and those with STEMI both during and after reperfusion. Prasugrel Hydrochloride 82-91 purinergic receptor P2Y12 Homo sapiens 52-57 25085573-7 2015 Our results show a higher residual PR in patients treated with prasugrel than those treated with ticagrelor (VerifyNow: 65.4 +- 60.6 vs. 26.0 +- 24.2 P2Y12 reaction units, p < 0.001 at 2-4 days, and 67.3 +- 62.5 vs. 21.1 +- 26.1, p < 0.001 at follow-up). Prasugrel Hydrochloride 63-72 purinergic receptor P2Y12 Homo sapiens 150-155 26224244-1 2015 INTRODUCTION: Clopidogrel, prasugrel, and ticagrelor are the currently available oral P2Y12 inhibitors for the treatment of ST-segment elevation myocardial infarction (STEMI), in association with aspirin. Prasugrel Hydrochloride 27-36 purinergic receptor P2Y12 Homo sapiens 86-91 25579761-6 2015 More importantly, it was recently shown that P2Y12 variants were associated with lung function in a large family-based asthma cohort and that the P2Y12 antagonist prasugrel tended to decrease bronchial hyper-reactivity to mannitol in patients with allergic bronchial asthma in a randomized, placebo controlled trial. Prasugrel Hydrochloride 163-172 purinergic receptor P2Y12 Homo sapiens 45-50 25579761-6 2015 More importantly, it was recently shown that P2Y12 variants were associated with lung function in a large family-based asthma cohort and that the P2Y12 antagonist prasugrel tended to decrease bronchial hyper-reactivity to mannitol in patients with allergic bronchial asthma in a randomized, placebo controlled trial. Prasugrel Hydrochloride 163-172 purinergic receptor P2Y12 Homo sapiens 146-151 25737192-1 2015 AIM: Prasugrel is a novel platelet P2Y12 receptor blocker with a faster onset of action and greater platelet inhibition with less response variability than clopidogrel. Prasugrel Hydrochloride 5-14 purinergic receptor P2Y12 Homo sapiens 35-40 26677375-4 2015 Prasugrel (a third generation thienopyridine) and ticagrelor (a cyclopentyl-triazolo-pyrimidine) feature more potent and predictable P2Y12-inhibition compared to clopidogrel, which translates into improved ischemic outcomes. Prasugrel Hydrochloride 0-9 purinergic receptor P2Y12 Homo sapiens 133-138 25350775-8 2015 ADP-induced platelet reactivity was decreased in the patients treated with prasugrel or ticagrelor compared with those on clopidogrel (mean +- SD: 139 +- 71 vs. 313 +- 162 arbitrary units [AU]*min, p = 0.006), due to a more potent antiplatelet activity of the novel P2Y12 antagonists. Prasugrel Hydrochloride 75-84 purinergic receptor P2Y12 Homo sapiens 266-271 25696877-7 2014 Alternatively, 2 third-generation P2Y12 inhibitors are available: prasugrel and ticagrelor. Prasugrel Hydrochloride 66-75 purinergic receptor P2Y12 Homo sapiens 34-39 25524333-2 2014 OBJECTIVES: The oral P2Y12 antagonists ticagrelor and prasugrel have higher recommendations than clopidogrel, but it is unknown if administration before the start of PCI is beneficial. Prasugrel Hydrochloride 54-63 purinergic receptor P2Y12 Homo sapiens 21-26 25012577-0 2014 Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. Prasugrel Hydrochloride 0-9 purinergic receptor P2Y12 Homo sapiens 90-95 25267101-2 2014 New generation P2Y12 inhibitors, such as prasugrel and ticagrelor exert stronger and more consistent inhibition of the P2Y12 receptor. Prasugrel Hydrochloride 41-50 purinergic receptor P2Y12 Homo sapiens 15-20 25267101-2 2014 New generation P2Y12 inhibitors, such as prasugrel and ticagrelor exert stronger and more consistent inhibition of the P2Y12 receptor. Prasugrel Hydrochloride 41-50 purinergic receptor P2Y12 Homo sapiens 119-124 25359405-4 2014 The third generation P2Y12 receptor antagonists prasugrel and ticagrelor provide stronger platelet inhibition than clopidogrel and improve the clinical outcome in patients with ACS; however, it is still under discussion which P2Y12 antagonist fits best to which subgroup of ACS patients. Prasugrel Hydrochloride 48-57 purinergic receptor P2Y12 Homo sapiens 21-26 25359405-4 2014 The third generation P2Y12 receptor antagonists prasugrel and ticagrelor provide stronger platelet inhibition than clopidogrel and improve the clinical outcome in patients with ACS; however, it is still under discussion which P2Y12 antagonist fits best to which subgroup of ACS patients. Prasugrel Hydrochloride 48-57 purinergic receptor P2Y12 Homo sapiens 226-231 27122812-6 2014 The newer P2Y12 inhibitors, ticagrelor or prasugrel, have a more potent platelet inhibitory effect and can be used for STEMI patients prepared for primary PCI if there is no contraindication. Prasugrel Hydrochloride 42-51 purinergic receptor P2Y12 Homo sapiens 10-15 25037531-2 2014 Oral antiplatelet agents for secondary prevention include the cyclo-oxygenase-1 inhibitor aspirin, and the ADP dependent P2Y12 inhibitors clopidogrel, prasugrel and ticagrelor. Prasugrel Hydrochloride 151-160 purinergic receptor P2Y12 Homo sapiens 121-126 24745727-2 2014 Dual anti-platelet therapy with acetylsalicylic acid (ASA) and a P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) is the recommended strategy for patients undergoing a percutaneous coronary intervention (PCI), while patients that undergo coronary artery bypass grafting (CABG) are treated with ASA monotherapy. Prasugrel Hydrochloride 95-104 purinergic receptor P2Y12 Homo sapiens 65-70 24659260-11 2014 CONCLUSIONS: The reversible P2Y12 antagonists ticagrelor, cangrelor, and elinogrel have an increased incidence of dyspnea in increasing order when compared with irreversible P2Y12 inhibitors such as clopidogrel or prasugrel. Prasugrel Hydrochloride 214-223 purinergic receptor P2Y12 Homo sapiens 28-33 25163307-4 2014 New generation of P2Y12 ADP antagonists including prasugrel and ticagrelor are available, but only in patients with acute coronary syndrome. Prasugrel Hydrochloride 50-59 purinergic receptor P2Y12 Homo sapiens 18-23 25071373-3 2014 Recently, introduction of new oral P2Y12 inhibitors (prasugrel, ticagrelor), with a faster and more pronounced antiplatelet effect, have decreased the use of abciximab even in patients with STEMI. Prasugrel Hydrochloride 53-62 purinergic receptor P2Y12 Homo sapiens 35-40 24189502-1 2014 BACKGROUND: The prevalence of contraindications/special warnings and precautions (CON/SWP) for clopidogrel, prasugrel and ticagrelor use is not adequately studied and might affect P2Y12 inhibitor choice in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). Prasugrel Hydrochloride 108-117 purinergic receptor P2Y12 Homo sapiens 180-185 24534451-1 2014 OBJECTIVE: New P2Y12 inhibitors can be classified as oral (prasugrel and ticagrelor) and intravenous drugs (cangrelor and elinogrel). Prasugrel Hydrochloride 59-68 purinergic receptor P2Y12 Homo sapiens 15-20 24534451-10 2014 An increase in TIMI major bleeding was observed only by prasugrel among the new P2Y12 inhibitors. Prasugrel Hydrochloride 56-65 purinergic receptor P2Y12 Homo sapiens 80-85 24668226-5 2014 At hour 2, prasugrel 100 mg over 60 mg loading dose significantly reduced high platelet reactivity rates from 28.6% to 8.5% (>=230 P2Y12 reaction units threshold; P=0.036) and from 31.4% to 10.6% (>=208 P2Y12 reaction units threshold; P=0.024), whereas resulted in lower rate of <=20% platelet inhibition (23.4% versus 51.4%; P=0.009). Prasugrel Hydrochloride 11-20 purinergic receptor P2Y12 Homo sapiens 134-139 24668226-5 2014 At hour 2, prasugrel 100 mg over 60 mg loading dose significantly reduced high platelet reactivity rates from 28.6% to 8.5% (>=230 P2Y12 reaction units threshold; P=0.036) and from 31.4% to 10.6% (>=208 P2Y12 reaction units threshold; P=0.024), whereas resulted in lower rate of <=20% platelet inhibition (23.4% versus 51.4%; P=0.009). Prasugrel Hydrochloride 11-20 purinergic receptor P2Y12 Homo sapiens 209-214 24630878-0 2014 Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients. Prasugrel Hydrochloride 86-95 purinergic receptor P2Y12 Homo sapiens 49-54 24630878-2 2014 BACKGROUND: Despite its more potent and rapid antiplatelet effects compared with clopidogrel, recent studies have shown variability in prasugrel-mediated P2Y12 receptor inhibition, particularly in high-risk settings. Prasugrel Hydrochloride 135-144 purinergic receptor P2Y12 Homo sapiens 154-159 24630878-11 2014 CONCLUSIONS: In patients on maintenance prasugrel therapy exposed to a reloading dose (30 or 60 mg) of prasugrel, in vitro cangrelor is associated with further platelet P2Y12 receptor inhibitory effects. Prasugrel Hydrochloride 103-112 purinergic receptor P2Y12 Homo sapiens 169-174 24670650-4 2014 P2Y12R regulates platelet activation and thrombus formation, and several antithrombotic drugs targeting P2Y12R--including the prodrugs clopidogrel (Plavix) and prasugrel (Effient) that are metabolized and bind covalently, and the nucleoside analogue ticagrelor (Brilinta) that acts directly on the receptor--have been approved for the prevention of stroke and myocardial infarction. Prasugrel Hydrochloride 160-169 purinergic receptor P2Y12 Homo sapiens 0-6 24670650-4 2014 P2Y12R regulates platelet activation and thrombus formation, and several antithrombotic drugs targeting P2Y12R--including the prodrugs clopidogrel (Plavix) and prasugrel (Effient) that are metabolized and bind covalently, and the nucleoside analogue ticagrelor (Brilinta) that acts directly on the receptor--have been approved for the prevention of stroke and myocardial infarction. Prasugrel Hydrochloride 160-169 purinergic receptor P2Y12 Homo sapiens 104-110 24670650-4 2014 P2Y12R regulates platelet activation and thrombus formation, and several antithrombotic drugs targeting P2Y12R--including the prodrugs clopidogrel (Plavix) and prasugrel (Effient) that are metabolized and bind covalently, and the nucleoside analogue ticagrelor (Brilinta) that acts directly on the receptor--have been approved for the prevention of stroke and myocardial infarction. Prasugrel Hydrochloride 171-178 purinergic receptor P2Y12 Homo sapiens 104-110 24732921-12 2014 CONCLUSIONS: With prasugrel as an antiplatelet treatment option, contemporary practice shows low uptake of prasugrel and delays in P2Y12 antagonist initiation among NSTEMI patients. Prasugrel Hydrochloride 18-27 purinergic receptor P2Y12 Homo sapiens 131-136 24555443-1 2014 INTRODUCTION: Prasugrel is a novel P2Y12 inhibitor approved for treatment of patients with acute coronary syndrome (ACS) who undergo percutaneous coronary intervention (PCI). Prasugrel Hydrochloride 14-23 purinergic receptor P2Y12 Homo sapiens 35-40 24529662-1 2014 Prasugrel and ticagrelor are next-generation antiplatelet agents that provide a rapider and more potent inhibition of platelet P2Y12 receptor than clopidogrel. Prasugrel Hydrochloride 0-9 purinergic receptor P2Y12 Homo sapiens 127-132 23221279-3 2014 In order to overcome this limitation, prasugrel and ticagrelor, newer P2Y12 inhibitors, have been developed and approved for clinical use. Prasugrel Hydrochloride 38-47 purinergic receptor P2Y12 Homo sapiens 70-75 24309957-4 2014 However, higher doses of aspirin have not been shown to have an adverse interaction with the potent P2Y12 inhibition provided by prasugrel and double-dose clopidogrel (Journal of the American College of Cardiology, 2013, in press; N Engl J Med 363: 930-942, 2010). Prasugrel Hydrochloride 129-138 purinergic receptor P2Y12 Homo sapiens 100-105 24071994-1 2014 In patients pretreated with P2Y12 receptor inhibitors who need to undergo non-emergent cardiac or major non-cardiac surgery, current guidelines of the European Society of Cardiology recommend postponing surgery for at least five days after last intake of clopidogrel or ticagrelor, and for seven days after last intake of prasugrel, unless there is high risk of ischemic events. Prasugrel Hydrochloride 322-331 purinergic receptor P2Y12 Homo sapiens 28-33 24337310-2 2014 Dual antiplatelet therapy composed of aspirin plus a third generation P2Y12 inhibitor (prasugrel or ticagrelor) represents the gold standard, while aspirin plus second generation P2Y12 inhibitor (clopidogrel) may be used as an alternative in the presence of contraindications for third generation P2Y12 inhibitors and/or a high risk of bleeding. Prasugrel Hydrochloride 87-96 purinergic receptor P2Y12 Homo sapiens 70-75 24799926-5 2014 Currently, the most important role in the process of platelet inhibition is played by ADP P2Y12 blockers: clopidogrel, prasugrel and ticagrelor. Prasugrel Hydrochloride 119-128 purinergic receptor P2Y12 Homo sapiens 90-95 23584598-3 2014 In recent years, newly developed P2Y12 antagonists, such as prasugrel and ticagrelor, have proven to be of higher efficacy and less resistance. Prasugrel Hydrochloride 60-69 purinergic receptor P2Y12 Homo sapiens 33-38 24406062-3 2014 Whereas the irreversible P2Y12 receptor inhibitors clopidogrel and prasugrel are prodrugs requiring cytochrome P450 (CYP) enzymes for metabolic activation, such activation is not necessary for the direct-acting reversible P2Y12 receptor inhibitor ticagrelor. Prasugrel Hydrochloride 67-76 purinergic receptor P2Y12 Homo sapiens 25-30 24406062-3 2014 Whereas the irreversible P2Y12 receptor inhibitors clopidogrel and prasugrel are prodrugs requiring cytochrome P450 (CYP) enzymes for metabolic activation, such activation is not necessary for the direct-acting reversible P2Y12 receptor inhibitor ticagrelor. Prasugrel Hydrochloride 67-76 purinergic receptor P2Y12 Homo sapiens 222-227 24262612-3 2013 High on-treatment platelet reactivity, which is common in clopidogrel-treated patients, and its clinical implications led to the development of the more effective platelet P2Y12 inhibitors prasugrel (a third-generation thienopyridine) and ticagrelor (a cyclopentyl-triazolo-pyrimidine). Prasugrel Hydrochloride 189-198 purinergic receptor P2Y12 Homo sapiens 172-177 26118162-2 2013 Clopidogrel and prasugrel act on P2Y12 platelet surface receptors. Prasugrel Hydrochloride 16-25 purinergic receptor P2Y12 Homo sapiens 33-38 24378838-5 2013 The new, more potent P2Y12 inhibitors, prasugrel and ticagrelor, have shown improved antithrombotic effects compared with clopidogrel in patients with ACS (with or without ST-segment elevation myocardial infarction) in landmark trials, even if they were associated with an increased risk of major bleeding. Prasugrel Hydrochloride 39-48 purinergic receptor P2Y12 Homo sapiens 21-26 24378838-7 2013 Importantly, both clopidogrel and prasugrel are prodrugs, i.e., they need to be converted in vivo into active metabolites that selectively and irreversibly bind the P2Y12 receptor. Prasugrel Hydrochloride 34-43 purinergic receptor P2Y12 Homo sapiens 165-170 24155721-3 2013 For next generation antiplatelet agents such as Ticagrelor and Prasugrel, these new P2Y12 receptor inhibitors form the cornerstone of therapy for patients with acute coronary syndrome (ACS) or undergoing percutaneous interventions. Prasugrel Hydrochloride 63-72 purinergic receptor P2Y12 Homo sapiens 84-89 23839753-7 2013 FINDINGS: Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor (eg, ticlopidine, clopidogrel, prasugrel, ticagrelor) reduces the risk of stent thrombosis and subsequent cardiovascular events post-PCI (number needed to treat, 33-53) and is the current standard of care. Prasugrel Hydrochloride 102-111 purinergic receptor P2Y12 Homo sapiens 55-60 24003163-6 2013 Platelet P2Y12 receptors are the targets of very widely used antithrombotic drugs such as clopidogrel, prasugrel, and ticagrelor. Prasugrel Hydrochloride 103-112 purinergic receptor P2Y12 Homo sapiens 9-14 23991622-2 2013 We evaluated the effect of administering the P2Y12 antagonist prasugrel at the time of diagnosis versus administering it after the coronary angiography if percutaneous coronary intervention (PCI) was indicated. Prasugrel Hydrochloride 62-71 purinergic receptor P2Y12 Homo sapiens 45-50 23612493-2 2013 P2Y12 receptor is the major platelet receptor that mediates ADP-induced aggregation, P2Y12 receptor inhibitors such as clopidogrel and prasugrel inhibit platelet aggregation, and thus, they are used in the treatment and prevention of coronary artery disease. Prasugrel Hydrochloride 135-144 purinergic receptor P2Y12 Homo sapiens 0-5 23905638-6 2013 Recently, P2Y12 receptor antagonists more potent than clopidogrel (e.g., prasugrel and ticagrelor) have been approved for patients with acute coronary syndromes and those undergoing percutaneous coronary interventions; these drugs provide greater platelet inhibition than clopidogrel. Prasugrel Hydrochloride 73-82 purinergic receptor P2Y12 Homo sapiens 10-15 22619468-8 2013 All patients who had follow-up studies of P2Y12 inhibition had immediate therapeutic response to prasugrel. Prasugrel Hydrochloride 97-106 purinergic receptor P2Y12 Homo sapiens 42-47 23612493-2 2013 P2Y12 receptor is the major platelet receptor that mediates ADP-induced aggregation, P2Y12 receptor inhibitors such as clopidogrel and prasugrel inhibit platelet aggregation, and thus, they are used in the treatment and prevention of coronary artery disease. Prasugrel Hydrochloride 135-144 purinergic receptor P2Y12 Homo sapiens 85-90 23171128-1 2013 AIMS: Prasugrel is a novel thienopyridine P2Y12 adenosine diphosphate (ADP) receptor antagonist that inhibits ADP-mediated platelet activation and aggregation. Prasugrel Hydrochloride 6-15 purinergic receptor P2Y12 Homo sapiens 42-47 23314910-4 2013 For new P2Y12 blockers, such as prasugrel, with less variability of platelet inhibition, these interactions are not significant; accordingly, no dose adjustment is required. Prasugrel Hydrochloride 32-41 purinergic receptor P2Y12 Homo sapiens 8-13 23543615-4 2013 In order to reduce the incidence of HPR, the more potent P2Y12 receptor inhibitors prasugrel and ticagrelor are used. Prasugrel Hydrochloride 83-92 purinergic receptor P2Y12 Homo sapiens 57-62 23283759-3 2013 Different strategies have been tested to overcome this phenomenon, such as increase in clopidogrel loading and maintenance doses and use of newer P2Y12 inhibitors (prasugrel and ticagrelor), which are by now indicated for patients with acute coronary syndromes; the latter agents have been associated with stronger antiplatelet effect than clopidogrel even in patients with stable coronary disease, but further studies are needed to test their net clinical benefit in this setting (reduction of ischemic events without increase in bleeding). Prasugrel Hydrochloride 164-173 purinergic receptor P2Y12 Homo sapiens 146-151 23397280-2 2013 The shortcomings of the most commonly used P2Y12 receptor inhibitor clopidogrel-that is its delayed onset of action, its interindividual response variability, and the phenomenon of high on-treatment platelet reactivity-led to the development of more potent P2Y12 receptor inhibitors (prasugrel and ticagrelor) that proved their superiority in terms of reducing thrombotic events compared to clopidogrel. Prasugrel Hydrochloride 284-293 purinergic receptor P2Y12 Homo sapiens 43-48 23397280-2 2013 The shortcomings of the most commonly used P2Y12 receptor inhibitor clopidogrel-that is its delayed onset of action, its interindividual response variability, and the phenomenon of high on-treatment platelet reactivity-led to the development of more potent P2Y12 receptor inhibitors (prasugrel and ticagrelor) that proved their superiority in terms of reducing thrombotic events compared to clopidogrel. Prasugrel Hydrochloride 284-293 purinergic receptor P2Y12 Homo sapiens 257-262 23397280-4 2013 Thus, it still warrants further investigation if a tailored, platelet function guided, antiplatelet therapy in ACS patients with the available P2Y12 receptor inhibitors prasugrel, ticagrelor, and clopidogrel can lead to improved patients outcome. Prasugrel Hydrochloride 169-178 purinergic receptor P2Y12 Homo sapiens 143-148 22338575-3 2012 According to the present guidelines, a dual antiplatelet treatment regimen consisting of aspirin and a P2Y12 receptor inhibitor such as clopidogrel, prasugrel or ticagrelor is routinely administered to ACS patients and to patients undergoing PCI in order to prevent thrombotic vessel occlusions. Prasugrel Hydrochloride 149-158 purinergic receptor P2Y12 Homo sapiens 103-108 22192279-4 2013 Newer, more potent P2Y12 inhibitors like prasugrel and ticagrelor have been introduced recently and present a particularly favorable action profile for the highly prethrombotic milieu of STEMI. Prasugrel Hydrochloride 41-50 purinergic receptor P2Y12 Homo sapiens 19-24 24107485-2 2013 Additionally, novel P2Y12 receptor antagonists such as prasugrel and ticagrelor are even recommended over clopidogrel in certain clinical guidelines. Prasugrel Hydrochloride 55-64 purinergic receptor P2Y12 Homo sapiens 20-25 27323431-5 2013 The fact that the genetic and pharmacokinetic properties of clopidogrel, a P2Y(12) inhibitor, cause insufficient antiplatelet efficacy and inadequate offset of action has led to the introduction of new P2Y(12) inhibitors such as prasugrel, ticagrelor and cangrelor, which offer an improved antiplatelet efficacy with a bleeding risk within acceptable limits. Prasugrel Hydrochloride 229-238 purinergic receptor P2Y12 Homo sapiens 75-82 27323431-5 2013 The fact that the genetic and pharmacokinetic properties of clopidogrel, a P2Y(12) inhibitor, cause insufficient antiplatelet efficacy and inadequate offset of action has led to the introduction of new P2Y(12) inhibitors such as prasugrel, ticagrelor and cangrelor, which offer an improved antiplatelet efficacy with a bleeding risk within acceptable limits. Prasugrel Hydrochloride 229-238 purinergic receptor P2Y12 Homo sapiens 202-209 23414938-5 2013 Platelet function by VerifyNow P2Y12 and vasodilator-stimulated phosphoprotein assays at days 10 and 30 were significantly inhibited in prasugrel- compared with placebo-treated SCD patients. Prasugrel Hydrochloride 137-146 purinergic receptor P2Y12 Homo sapiens 32-37 22338575-5 2012 Along with this development, more potent P2Y12 receptor inhibitors like prasugrel and ticagrelor are substitutes for clopidogrel in specific circumstances such as in ACS patients or in patients who do not adequately respond to standard clopidogrel treatment. Prasugrel Hydrochloride 72-81 purinergic receptor P2Y12 Homo sapiens 41-46 21895760-4 2012 Prasugrel is an oral pro-drug leading to irreversible blockade of the P2Y12 receptor and is approved worldwide for ACS PCI. Prasugrel Hydrochloride 0-9 purinergic receptor P2Y12 Homo sapiens 70-75 22789884-2 2012 BACKGROUND: Newer P2Y12 inhibitors like prasugrel and ticagrelor provide stronger platelet inhibition compared with clopidogrel. Prasugrel Hydrochloride 40-49 purinergic receptor P2Y12 Homo sapiens 18-23 22692976-1 2012 Prasugrel, a thienopyridine ADP receptor antagonist, is an orally administered prodrug requiring in vivo metabolism to form the active metabolite that irreversibly inhibits platelet activation and aggregation mediated by the P2Y12[sub 12] receptor. Prasugrel Hydrochloride 0-9 purinergic receptor P2Y12 Homo sapiens 225-230 21895760-7 2012 Both prasugrel and ticagrelor, opposed to clopidogrel, have shown that stronger P2Y12 inhibition led respectively to significant 19 and 16% relative risk reduction of a similar primary end point combining cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. Prasugrel Hydrochloride 5-14 purinergic receptor P2Y12 Homo sapiens 80-85 22906899-3 2012 P2Y(12) inhibitors include ticlopidine (now rarely used), clopidogrel, prasugrel, and ticagrelor. Prasugrel Hydrochloride 71-80 purinergic receptor P2Y12 Homo sapiens 0-7 22183178-7 2012 The objectives of this review are to discuss the pharmacological limitations of the P2Y12 inhibitor clopidogrel, and describe the novel alternative P2Y12 inhibitors prasugrel and ticagrelor and the clinical implications of the introduction of these new medicines. Prasugrel Hydrochloride 165-174 purinergic receptor P2Y12 Homo sapiens 148-153 22839447-3 2012 Compared with high dose clopidogrel, prasugrel inhibited P2Y12-mediated platelet aggregation faster and to a greater extent. Prasugrel Hydrochloride 37-46 purinergic receptor P2Y12 Homo sapiens 57-62 22360514-2 2012 Ticlopidine, Clopidogrel, Prasugrel, Ticagrelor, Cangrelor and Elinogrel are the P2Y12 inhibitors that act as antiplatelet drugs. Prasugrel Hydrochloride 26-35 purinergic receptor P2Y12 Homo sapiens 81-86 22918731-2 2012 Among the P2Y12 receptor inhibitors, the group of thienopyridines include ticlopidine, clopidogrel and prasugrel, all of which are orally administered prodrugs leading to irreversible P2Y12 receptor inhibition. Prasugrel Hydrochloride 103-112 purinergic receptor P2Y12 Homo sapiens 10-15 22918731-2 2012 Among the P2Y12 receptor inhibitors, the group of thienopyridines include ticlopidine, clopidogrel and prasugrel, all of which are orally administered prodrugs leading to irreversible P2Y12 receptor inhibition. Prasugrel Hydrochloride 103-112 purinergic receptor P2Y12 Homo sapiens 184-189 21812912-0 2011 Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel. Prasugrel Hydrochloride 108-117 purinergic receptor P2Y12 Homo sapiens 51-56 21985070-5 2011 RESULTS: The primary endpoint of platelet reactivity (PR, measured in P2Y12 reaction units [PRU]) was lower in patients receiving prasugrel (least squares [LS] estimate 156.6, 95% confidence interval [CI] 132.2-181.1) than in those receiving high-dose clopidogrel (LS 279.9, 95% CI 255.4-304.3), P < 0.001). Prasugrel Hydrochloride 130-139 purinergic receptor P2Y12 Homo sapiens 70-75 21946108-1 2011 Thienopyridines (ticlopidine, clopidogrel and prasugrel) are pro-drugs that require metabolism to exhibit a critical thiol group in the active form that binds to the P2Y12 receptor to inhibit platelet activation and prevent thrombus formation in vivo. Prasugrel Hydrochloride 46-55 purinergic receptor P2Y12 Homo sapiens 166-171 21392598-1 2011 Despite the proven efficacy of dual antiplatelet therapy with aspirin and one of the first-generation P2Y(12) antagonists (clopidogrel, prasugrel) in patients with atherothrombotic disease, residual ischemic risk remains substantial, and bleeding rates are increased. Prasugrel Hydrochloride 136-145 purinergic receptor P2Y12 Homo sapiens 102-109 21479342-8 2011 Compared to clopidogrel, new drugs inhibiting P2Y12, such as prasugrel and ticagrelor, decrease the risk of cardiovascular events and increase the risk of bleeding complications, because they adequately inhibit P2Y12-dependent platelet function in the vast majority of treated patients. Prasugrel Hydrochloride 61-70 purinergic receptor P2Y12 Homo sapiens 211-216 21252171-7 2011 Greater platelet inhibition by VerifyNow P2Y12 was achieved by prasugrel compared with clopidogrel at 4 h post-LD (least squares mean, 89.3 vs. 27.7%, P< 0.0001; primary endpoint). Prasugrel Hydrochloride 64-73 purinergic receptor P2Y12 Homo sapiens 42-47 21505714-2 2011 Simultaneous inhibition of blood platelet cyclooxygenase-1 by aspirin and of the P2Y12 receptor by clopidogrel or prasugrel is currently recommended in this setting. Prasugrel Hydrochloride 114-123 purinergic receptor P2Y12 Homo sapiens 81-86 21713327-2 2011 It was the objective of this study to determine whether the intrinsic platelet response to adenosine diphosphate (ADP) before thienopyridine exposure contributes to residual platelet reactivity to ADP despite high level P2Y12 blockade by prasugrel (60 mg loading dose [LD]), 10 mg daily maintenance dose [MD]) or high-dose clopidogrel (600 mg LD, 150 mg daily MD). Prasugrel Hydrochloride 238-247 purinergic receptor P2Y12 Homo sapiens 220-225 21479342-8 2011 Compared to clopidogrel, new drugs inhibiting P2Y12, such as prasugrel and ticagrelor, decrease the risk of cardiovascular events and increase the risk of bleeding complications, because they adequately inhibit P2Y12-dependent platelet function in the vast majority of treated patients. Prasugrel Hydrochloride 61-70 purinergic receptor P2Y12 Homo sapiens 46-51 20659022-15 2010 Novel P2Y12 receptor inhibitors prasugrel and ticagrelor have been shown to be superior to clopidogrel in large randomized trials. Prasugrel Hydrochloride 32-41 purinergic receptor P2Y12 Homo sapiens 6-11 20966167-8 2011 New drugs, such as prasugrel and ticagrelor, which effectively inhibit P2Y12 in the majority of patients, proved to be more efficacious than clopdidogrel in preventing major cardiovascular events. Prasugrel Hydrochloride 19-28 purinergic receptor P2Y12 Homo sapiens 71-76 21262444-5 2011 The use of new P2Y12 inhibitors, such as prasugrel and ticagrelor, which adequately inhibit P2Y12-dependent platelet function in the vast majority of treated subjects, appears the best solution to the problem of clopidogrel resistance. Prasugrel Hydrochloride 41-50 purinergic receptor P2Y12 Homo sapiens 15-20 21262444-5 2011 The use of new P2Y12 inhibitors, such as prasugrel and ticagrelor, which adequately inhibit P2Y12-dependent platelet function in the vast majority of treated subjects, appears the best solution to the problem of clopidogrel resistance. Prasugrel Hydrochloride 41-50 purinergic receptor P2Y12 Homo sapiens 92-97 21591981-4 2011 Here, we investigate the ability of the P2Y12 antagonists cangrelor, ticagrelor and prasugrel active metabolite (PAM), and the EP3 antagonist DG-041 to promote the inhibitory effects of modulators of platelet aggregation that act via cAMP. Prasugrel Hydrochloride 84-93 purinergic receptor P2Y12 Homo sapiens 40-45 21068525-7 2010 The present article reviews data on the clinical impact of enhanced P2Y12 inhibition with either higher clopidogrel dosing or new oral antiplatelet agents, including prasugrel and ticagrelor, in the setting of STEMI, focusing on results in the setting of primary PCI. Prasugrel Hydrochloride 166-175 purinergic receptor P2Y12 Homo sapiens 68-73 21057581-9 2010 However, like the active metabolite of clopidogrel, prasugrel binds irreversibly to the P2Y12 ADP receptor site, causing inhibition of platelet aggregation for the life of the platelet. Prasugrel Hydrochloride 52-61 purinergic receptor P2Y12 Homo sapiens 88-93 20431852-1 2010 The thienopyridine P2Y12 receptor antagonists clopidogrel and prasugrel prevent arterial thrombosis and are routinely used following percutaneous coronary intervention. Prasugrel Hydrochloride 62-71 purinergic receptor P2Y12 Homo sapiens 19-24 20431852-3 2010 These studies utilised the active metabolite of prasugrel (R-138727) to achieve a range of P2Y12 blockade in vitro and assessed several aspects of platelet function. Prasugrel Hydrochloride 48-57 purinergic receptor P2Y12 Homo sapiens 91-96 20372759-4 2010 Recently, 2 novel third generation oral inhibitors of P2Y12 receptors, prasugrel and ticagrelor, have undergone clinical evaluation with promising results. Prasugrel Hydrochloride 71-80 purinergic receptor P2Y12 Homo sapiens 54-59 21071695-6 2010 Effects induced by 2-methylthio-ADP were prevented by RNA interference-mediated knockdown of P2Y12 and a selective P2Y12-antagonist R-138727, the active metabolite of prasugrel. Prasugrel Hydrochloride 167-176 purinergic receptor P2Y12 Homo sapiens 115-120 21189531-2 2010 Prasugrel (Efient), a thienopyridine of third generation, is a prodrug that, like clopidogrel, requires conversion to an active metabolite before binding to the platelet P2Y12 receptor to confer antiplatelet activity. Prasugrel Hydrochloride 0-9 purinergic receptor P2Y12 Homo sapiens 170-175 18752581-1 2008 BACKGROUND: The P2Y(12) receptor plays a crucial role in platelet aggregation and is the target of platelet aggregation inhibitors, including the thienopyridine compound prasugrel. Prasugrel Hydrochloride 170-179 purinergic receptor P2Y12 Homo sapiens 16-23 19550317-6 2009 Novel P2Y12 antagonists (prasugrel, ticagrelor, cangrelor, and elinogrel) that have advantages over clopidogrel - including more rapid, less variable, and more complete inhibition of platelet function - are in various phases of development. Prasugrel Hydrochloride 25-34 purinergic receptor P2Y12 Homo sapiens 6-11 19698014-0 2009 Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. Prasugrel Hydrochloride 41-50 purinergic receptor P2Y12 Homo sapiens 69-74 19249429-0 2009 Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. Prasugrel Hydrochloride 104-113 purinergic receptor P2Y12 Homo sapiens 73-78 19249429-11 2009 VN-P2Y12 also correlated to exposure to the active metabolite of prasugrel and clopidogrel up to levels associated with assumed saturation of the P2Y(12) receptor. Prasugrel Hydrochloride 65-74 purinergic receptor P2Y12 Homo sapiens 3-8 19050170-0 2009 P2Y12 inhibitors in cardiovascular disease: focus on prasugrel. Prasugrel Hydrochloride 53-62 purinergic receptor P2Y12 Homo sapiens 0-5 18506123-22 2008 Prasugrel, a novel thienopyridine, Cangrelor and AZD 6140 represent newer P2Y12 antagonists. Prasugrel Hydrochloride 0-9 purinergic receptor P2Y12 Homo sapiens 74-79 18991794-7 2008 Among these are thrombin receptor antagonists, such as SCH530348 and P2Y12 receptor antagonists, such as prasugrel, cangrelor, and AZD6140. Prasugrel Hydrochloride 105-114 purinergic receptor P2Y12 Homo sapiens 69-74